Nature Reviews Drug Discovery
- ️Mon Dec 16 2024
Featured
-
GPCR drug discovery: new agents, targets and indications
G protein-coupled receptors (GPCRs) are one of the largest families of drug targets. This Review analyses drug discovery trends for GPCRs, covering compounds, targets and indications that have reached regulatory approval or that are being investigated in clinical trials, and also highlights the potential of untapped target–disease associations and pathway-biased signalling.
- Javier Sánchez Lorente
- Aleksandr V. Sokolov
- David E. Gloriam
Review Article03 Mar 2025
-
MYC in cancer: from undruggable target to clinical trials
Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on the most recently described inhibitors and those that have reached clinical trials.
- Jonathan R. Whitfield
- Laura Soucek
Review Article19 Feb 2025
-
Voltage-gated sodium channels in excitable cells as drug targets
The family of voltage-gated sodium channels (NaVs) are key mediators of electrical signals in excitable cells. In their broad Review, Waxman and colleagues discuss the potential to target NaVs in neurons, cardiac and skeletal muscle cells for the treatment of various neurological and muscular disorders.
- Matthew Alsaloum
- Sulayman D. Dib-Hajj
- Stephen G. Waxman
Review Article03 Feb 2025
Announcements
-
-
Dealmaking shifts for cell and gene therapies
From Biopharma Dealmakers: Deals and funding for cell and gene therapy companies have been muted in the past year compared to recent peaks, but emerging technologies that are advancing treatments for autoimmune diseases and in vivo engineering could reinvigorate the field.
Latest Reviews & Analysis
-
-
GPCR drug discovery: new agents, targets and indications
G protein-coupled receptors (GPCRs) are one of the largest families of drug targets. This Review analyses drug discovery trends for GPCRs, covering compounds, targets and indications that have reached regulatory approval or that are being investigated in clinical trials, and also highlights the potential of untapped target–disease associations and pathway-biased signalling.
-
MYC in cancer: from undruggable target to clinical trials
Oncogene MYC has been considered ‘undruggable’ for many decades. This Review provides an overview of the various strategies to inhibit MYC, focusing on the most recently described inhibitors and those that have reached clinical trials.
-
Novel strategies to manage CAR-T cell toxicity
Treatment with chimeric antigen receptor (CAR)-T cell therapies is associated with important immune-related adverse events. In this Review, the authors discuss the standard-of-care management for cytokine release and immune effector cell-associated neurotoxicity syndromes, and the potential of other T cell druggable targets as well as cellular engineering strategies to develop safer CAR-T cells.
-
Voltage-gated sodium channels in excitable cells as drug targets
The family of voltage-gated sodium channels (NaVs) are key mediators of electrical signals in excitable cells. In their broad Review, Waxman and colleagues discuss the potential to target NaVs in neurons, cardiac and skeletal muscle cells for the treatment of various neurological and muscular disorders.
-
Enhancing immunity during ageing by targeting interactions within the tissue environment
Immune dysfunction increases with age owing to cellular senescence and low-grade inflammation, processes that drive each other during ageing. This Review discusses the potential of therapeutic approaches that target interactions between the tissue environment and the immune system by eliminating senescent cells, inhibiting inflammation and boosting immune function.
-
-
Collections
Life sciences and biotech in Canada
In this spotlight, we discover more to Canada’s biotech scene by providing an overview of the market landscape and showcasing some of its innovative companies.
Collection 20 Dec 2024
